Skip to main content

Blog

FDA Expands ELEVIDYS Label Indication for Ages 4 Years and Older

...

PAAC Travel Tips

...

Newborn Screening for Duchenne: PPMD’s Collaborative Future Planning Efforts

...

Cranbury Pharmaceuticals (Tris Pharma) Receives FDA Approval for First Generic Version of Emflaza® (deflazacort) for Duchenne

...

Build Your Own Care Binder at PPMD’s 30th Annual Conference

...

Pfizer Shares Update on Phase 3 Study of Investigational Mini-Dystrophin Gene Therapy

...

Consensus Statement Featuring Expert Insights from PPMD’s Certified Duchenne Care Centers on Access to Novel Therapies for Duchenne Published

...

Roche Announces Phase II Open-Label SHIELD DMD Study to Assess Effect of Satralizumab on Bone Health in Duchenne

...

Summer Fun: Accessible Activities for All Ages and Interests

...

Capricor Therapeutics Announces Positive 3-Year Efficacy Results from HOPE-2 Open Label Extension Study of CAP-1002

...